There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agilon Health (AGL – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report) with bullish sentiments.
Agilon Health (AGL)
Jefferies analyst Brian Tanquilut maintained a Buy rating on Agilon Health yesterday and set a price target of $35.00. The company’s shares closed last Thursday at $19.23, close to its 52-week low of $14.36.
According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of
Currently, the analyst consensus on Agilon Health is a Strong Buy with an average price target of $31.67.
BioMarin Pharmaceutical (BMRN)
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $100.00. The company’s shares closed last Thursday at $75.43.
According to TipRanks.com, Tewari is a 4-star analyst with an average return of
Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $113.31, a 45.8% upside from current levels. In a report issued on February 24, Truist Financial also reiterated a Buy rating on the stock with a $135.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AGL:
- Amazon Expects FTC’s Verdict on MGM Acquisition by Mid-March: Report
- Marvell (MRVL) Gets a Buy Rating from Susquehanna
- Broadcom (AVGO): New Buy Recommendation for This Technology Giant
- Noble Financial Believes Eagle Bulk Shipping (EGLE) Won’t Stop Here
- Colliers Securities Reiterates Their Hold Rating on Chembio Diagnostics (CEMI)